PDCD1 and adenocarcinoma: We selected a set of 94 adenocarcinomas including 14 cases with EGFR-sensitizing mutations with immune profiling by immunohistochemistry for ten immune markers (PD- L1, PD-1, CD3, CD4, CD8, CD45RO, CD57, CD68, FoxP3 and Granzyme B).